These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24043136)

  • 21. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine-based combination therapy for breast cancer: implications for nurses.
    Frye DK
    Oncol Nurs Forum; 2009 Jan; 36(1):105-13. PubMed ID: 19136344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
    Tong J; Xie G; He J; Li J; Pan F; Liang H
    J Biomed Biotechnol; 2011; 2011():740564. PubMed ID: 21403907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Jin K; Lan H; Xie B; He K; Xu Z; Li G; Han N; Teng L; Cao F
    Cancer Biol Ther; 2012 Jul; 13(9):737-44. PubMed ID: 22617773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
    Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW; Hashmi S; Bell D; Diasio RB
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
    Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
    Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
    Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
    Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
    Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
    Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
    Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
    Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
    Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 35. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
    Mayer RJ
    J Clin Oncol; 2001 Nov; 19(21):4093-6. PubMed ID: 11689576
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
    Rousseau F; Retornaz F; Joly F; Esterni B; Abadie-Lacourtoisie S; Fargeot P; Luporsi E; Servent V; Laguerre B; Brain E; Geneve J;
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):71-8. PubMed ID: 20356760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dramatic response of recalcitrant warts as a side effect of colorectal cancer treatment with oral capecitabine.
    Bel B; Lorton MH; Darut-Jouve A; Vabres P
    Eur J Dermatol; 2011; 21(5):789-90. PubMed ID: 21700544
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.